英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

intensifiers    
含硼铁合金

含硼铁合金


请选择你想看的字典辞典：
单词字典翻译
intensifiers查看　intensifiers　在百度字典中的解释百度英翻中〔查看〕
intensifiers查看　intensifiers　在Google字典中的解释Google英翻中〔查看〕
intensifiers查看　intensifiers　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Lotus
    Lotus Pharmaceutical (stock code: 1795 TT) is a fast-growing specialty pharmaceutical company headquartered in Taiwan As one of the largest specialty pharma companies in the region, Lotus focuses on developing, manufacturing, in-licensing and commercialising high-quality medicines across 90+ markets in the world With best-in-class R D capabilities and strong manufacturing platforms, Lotus
  • 美時 - lotuspharm. com
    美時製藥（股票代號：1795 TT）成立於台灣，是全球成長最快的專科製藥公司之一，專注於開發、製造、授權引進與商業化高品質藥品，產品已遍及至全球 90 多個市場。 憑藉堅實的技術實力與強大的製造平台，美時以自有研發與事業開發並行的複合式產品策略，持續打造高技術門檻的多元產品線，為
  • Product Overview - Lotus Pharm
    We market over 250 commercial products across 90+ markets globally, with pipeline supported by our hybrid R D+BD strategy With expertise in high‑barrier oncology and complex generics, we focus on addressing unmet medical needs Through targeted acquisitions and licensing of branded medicines, 505 (b) (2) products, biosimilars, and NCEs, we continue to build a differentiated portfolio that
  • Lotus reports September 2025 Revenue of NT$1,214 Million - lotuspharm. com
    Taipei, Taiwan, 9 October 2025 — Lotus Pharmaceutical Co , Ltd (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for September 2025 reaching NT$1,214 million, an increase of 2% year-over-year (YoY) compared to same period last year Lotus's September 2025 year-to-date (YTD) revenue stood at NT$14,248 million
  • 美時2020英文年報v5 - jp. lotuspharm. com
    To provide affordable solutions to patients and to maximize benefits and values for our employees and shareholders are always Lotus’ top priorities For sustainable growth, we keep expanding accessible markets worldwide with made-in-Taiwan products of high-quality and further enhanced our commercial networks via strategic alliance with Fuji Pharma Co , Ltd on top of our global licensing
  • Research Development - lotuspharm. com
    R D Competence Lotus operates a state-of-the-art formulation development center in India, supporting the development of high-potency oncology products as well as general pharmaceuticals Our R D organization brings together experienced specialists in formulation and analytical development, project management, intellectual property, clinical research, developmental quality, and packaging The
  • Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 . . .
    Taipei, Taiwan, January 10, 2024 — Lotus Pharmaceutical Co , Ltd (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company headquartered in Taiwan, is pleased to announce its unaudited consolidated revenues for December 2023 The company recorded NT$1,372 million in revenue, showcasing a significant 20 92% increase compared to the previous month and a 7 98% year-on-year growth
  • Lotus SupplierBridge
    Supplier portal for inviting, registering, and approving supplier data with BPM and SAP integration
  • Lotus Honoured as One of Asia’s Best Workplaces for the Fourth . . .
    Taipei, Taiwan, 15 August 2025 — Lotus Pharmaceutical Co , Ltd (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, proudly announces its continued recognition as one of Asia’s most exemplary employers, securing the “HR Asia Best Companies to Work for in Asia – Taiwan Region” award for a fourth year in a row This milestone underscores Lotus’s
  • Lotus Reported Unaudited February Revenues of NT$967 Million
    Taipei, Taiwan, March 10, 2025 — Lotus Pharmaceutical Co , Ltd (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, has disclosed its unaudited consolidated revenue for February 2024 of NT$967 million, with year-to-date revenue reaching NT$ 3,138 million, a 3% year-over-year increase February's revenue was influenced by customer stockpiling across most





中文字典-英文字典  2005-2009